Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine in TS Genotype-Directed Advanced Pancreatic Cancer
NCT00303927Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Dec 2005
- Primary completion
- Sep 2007
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of capecitabine in pancreatic cancer (PC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoints: 6-month Survival and Toxicity. Started Dec 2005; status: completed.
02
Drugs
capecitabine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00303927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00303927.